Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile

Fig. 5

GenSci059 anti-tumor activity results in tumor-bearing mouse models. PDX model results of subcutaneous xenotransplantation of Human non-Hodgkin lymphoma cell Raji (A), HL-60 (B) and small cell lung cancer cell LU2514 (C); D Inhibitory effect of GenSci059 combined with Rituximab on Raji tumor growth. P values for tumor volume analysis apply to the final time point as indicated in graphs and were calculated by Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page